SLC5A2 and chronic kidney disease: The 2024 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend the use of GLP-1RAs in “adults with T2D and CKD who have not achieved individualized glycemic targets despite use of metformin and SGLT2 inhibitor treatment” [58].